HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Molly C Carr Selected Research

Therapeutics

10/2020Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
9/2017Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy.
12/2014HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
10/2014Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
7/2005Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy.
6/2004Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Molly C Carr Research Topics

Disease

9Type 2 Diabetes Mellitus (MODY)
10/2020 - 07/2003
3Body Weight (Weight, Body)
09/2017 - 12/2014
3Dyslipidemias (Dyslipidemia)
06/2004 - 07/2003
3Metabolic Syndrome (Dysmetabolic Syndrome X)
06/2004 - 06/2003
2Hypoglycemia (Reactive Hypoglycemia)
10/2020 - 01/2017
2Weight Loss (Weight Reduction)
10/2020 - 12/2014
2Nausea
04/2017 - 10/2014
2Vomiting
04/2017 - 10/2014
2Hypertriglyceridemia
07/2005 - 06/2004
2Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial)
06/2004 - 07/2003
2Abdominal Obesity
03/2004 - 07/2003
1Weight Gain
09/2017
1Pancreatitis
04/2017
1Injection Site Reaction
04/2017
1Hyperglycemia
01/2017
1Diarrhea
10/2014
1Inflammation (Inflammations)
04/2009
1Insulin Resistance
04/2009
1Atherosclerosis
04/2009
1Cardiovascular Diseases (Cardiovascular Disease)
03/2006
1Menstruation Disturbances
03/2006
1Obesity
07/2003

Drug/Important Bio-Agent (IBA)

8rGLP-1 proteinIBA
10/2020 - 10/2014
5Glucose (Dextrose)FDA LinkGeneric
09/2017 - 06/2003
4Glucagon-Like Peptide-1 ReceptorIBA
10/2020 - 10/2014
3Insulin Glargine (Lantus)FDA Link
10/2020 - 12/2014
3Insulin (Novolin)FDA Link
10/2020 - 06/2003
3Hypoglycemic Agents (Hypoglycemics)IBA
09/2017 - 10/2014
3LipidsIBA
06/2004 - 06/2003
2Triglycerides (Triacylglycerol)IBA
07/2005 - 06/2003
2Estrogens (Estrogen)FDA Link
07/2005 - 06/2003
2HDL LipoproteinsIBA
06/2004 - 06/2003
2LDL Lipoproteins (beta Lipoproteins)IBA
06/2004 - 06/2003
2Lipase (Acid Lipase)FDA Link
03/2004 - 07/2003
1Insulin Lispro (Humalog)FDA Link
10/2020
1Pioglitazone (Actos)FDA Link
09/2017
1glimepiride (Amarel)FDA LinkGeneric
09/2017
1Glucagon-Like Peptide-1 Receptor AgonistsIBA
04/2017
1IncretinsIBA
04/2017
1Metformin (Glucophage)FDA LinkGeneric
12/2014
1Sitagliptin Phosphate (Januvia)FDA Link
10/2014
1AdipokinesIBA
04/2009
1AndrogensIBA
03/2006
1Hydrocortisone (Cortisol)FDA LinkGeneric
03/2006
1Selective Estrogen Receptor Modulators (SERM)IBA
07/2005
1Fibric Acids (Fibrates)IBA
07/2005
1Raloxifene Hydrochloride (Evista)FDA Link
07/2005
1ApolipoproteinsIBA
06/2004
1LDL CholesterolIBA
06/2004
1Niacin (Nicotinic Acid)FDA LinkGeneric
12/2003
1Dietary Fats (Dietary Fat)IBA
07/2003
1Lipoproteins (Lipoprotein)IBA
07/2003

Therapy/Procedure

6Therapeutics
10/2020 - 06/2004
1Glycemic Control
10/2020
1Injections
10/2020